7.02
+3.85%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Vaishali Pharma
Its shares trade on NSE under the ticker VAISHALI.NS. It has been listed since 22 August 2017. In the fiscal year to 31 March 2026, it reported revenue of ₹1.09bn and net income of ₹41.6m. At that date it held total assets of ₹1.23bn and shareholders' equity of ₹691.2m.
Vaishali Pharma Ltd. is a healthcare company, which engages in the marketing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2017-08-22. The firm is engaged in dealing in pharmaceutical ingredient, pharmaceutical formulations, surgical products, herbal and nutraceutical products, veterinary supplements operating in domestic and export market. In domestic markets, it is engaged in contract manufacturing and trading of active pharmaceuticals ingredient's (APIs) and supply of API's for export captive consumption. In export markets, it is engaged in manufacturing and export of pharmaceutical formulations; manufacturing and export of surgical products; manufacturing and export of veterinary products; and manufacturing and export of herbal and nutraceuticals products. Its product categories include API, formulation brands, formulations, herbal, nutraceuticals, oncology, surgical and veterinary, among others. The firm markets approximately 400 products in domestic and APIs has a product portfolio of more than 1,000 products for the overseas market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 22 Aug 2017
- Website
- vaishalipharma.com ↗
Leadership
Pay as last reported
- Mr. Atul VasaniChairman of the Board, Managing Director, since 2017₹5.4m
- Mr. Hemanth PathakChief Executive Officer
- Mr. Dewansh VasaniChief Financial Officer, Executive Director, since 2018
- Mr. Akshay JharkhandiCompany Secretary & Compliance Officer
- Ms. Jagruti VasaniWhole Time Director, since 2017₹1.2m
- Mr. Bhavesh UpadhyayAdditional Independent Director
- Mr. Ashvin GanatraNon-Executive Independent Director
- Mr. Prataprai GandhiNon-Executive Independent Director
- Mr. Manish VedNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Vaishali Pharma Ltd. markets 400 domestic products in the Indian market.
- The company has over 1,000 API products for overseas markets.
- Vaishali Pharma operates in multiple segments including oncology and veterinary.
Weaknesses
- The company's domestic market focuses on contract manufacturing of APIs.
- Vaishali Pharma relies on export markets for a significant portion of its revenue.
- The firm's product portfolio is limited to pharmaceuticals and related segments.
Opportunities
- Vaishali Pharma can expand its herbal and nutraceuticals product lines.
- The company can leverage its API manufacturing capabilities for new markets.
- Growing demand for oncology products presents a market opportunity.
Threats
- Dependence on export markets exposes Vaishali Pharma to international trade risks.
- Competition in the pharmaceutical industry may affect pricing strategies.
- Regulatory changes in the Indian healthcare sector could impact operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.